Novel organometallic chloroquine derivative inhibits tumor growth

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Autophagy is crucial in cancer development and therapy resistance.
• Chloroquine and hydroxychloroquine target lysosomal pathways but have limitations.
• Refractory tumors necessitate novel therapeutic strategies targeting cell death pathways.

Purpose of the Study:

• To introduce and evaluate cymanquine, a novel organometallic chloroquine derivative.
• To assess cymanquine's efficacy in overcoming limitations of traditional 4-aminoquinolines.
• To investigate cymanquine's potential as an anti-cancer therapy, particularly for drug-resistant melanoma.

Main Methods:

• In vitro assessment of cymanquine's potency in various human cancer cell lines at normal and reduced pH.
• Evaluation of lysosomal accumulation and autophagy blockade induced by cymanquine compared to chloroquine.
• In vivo studies using a mouse model of vemurafenib-resistant melanoma to assess tumor growth and drug combination efficacy.

Main Results:

• Cymanquine demonstrated greater potency than chloroquine (CQ) in vitro across diverse cancer cell lines, including melanoma, under normal and tumor-mimicking pH conditions.
• Cymanquine induced superior lysosomal accumulation and autophagy blockade compared to chloroquine and hydroxychloroquine.
• In vivo, cymanquine slowed tumor growth in a vemurafenib-resistant melanoma model and partially restored sensitivity to vemurafenib when used in combination.

Conclusions:

• Cymanquine exhibits enhanced bioactivity and overcomes the pH limitations of traditional 4-aminoquinolines.
• Cymanquine effectively inhibits autophagy by inducing lysosomal dysfunction.
• Cymanquine represents a promising therapeutic agent with superior in vitro and in vivo efficacy for refractory melanoma and potentially other cancers.